Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06340360 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) | PHASE2 | ACTIVE NOT_RECRUITING | 94 | — | — | Apr 2, 2024 | Aug 1, 2026 | Mar 31, 2026 | 26 | United States, Canada +1 |
The SALT score is the sum of percentage of hair loss in all areas with a maximum score of 100 (higher score indicates greater hair loss).
| Arm | Type | Description |
|---|---|---|
| Low Dose | EXPERIMENTAL | Rezpegaldesleukin Low Dose Every 2 weeks |
| High Dose | EXPERIMENTAL | Rezpegaldesleukin High Dose Every 2 weeks |
| Placebo | PLACEBO_COMPARATOR | Placebo Every 2 weeks |
| Name | Type | Description |
|---|---|---|
| Rezpegaldesleukin | DRUG | Pharmaceutical form: Injection solution Route of administration: subcutaneous |
| Placebo | DRUG | Pharmaceutical form: Injection solution Route of administration: subcutaneous |
Inclusion Criteria: * Adults who are at least 18 years and ≤60 years for males (≤70 years of age for females) old at the time of informed consent * Diagnosis of Alopecia Areata (AA) severity at screening and baseline: 1. severe to very severe AA (≥ 50% scalp involvement) as measured using the SA...